Thromb Haemost 2012; 107(05): 806-807
DOI: 10.1160/TH12-03-0164
Invited Editorial Focus
Schattauer GmbH

Should the commonly accepted definition of “unprovoked venous thrombembolism” be revisited?

Walter Ageno
1   Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Alessandro Squizzato
1   Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Francesco Dentali
1   Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
› Author Affiliations
Further Information

Publication History

Received: 13 March 2012

Accepted: 13 March 2012

Publication Date:
25 November 2017 (online)

 

Editorial on ► Tichelaar et al. Thromb Haemost 2012; 107: 827-837.

 
  • References

  • 1 White RH. The epidemiology of venous thromboembolism. Circulation. 2003 107. I-4-I-8.
  • 2 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
  • 3 Heit JA, Silverstein MD, Mohr DN. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
  • 4 Iorio A, Kearon C, Filippucci E. et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-1716.
  • 5 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2003; 18: 3078-3083.
  • 6 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease. Chest 2012; 141: e419S-e494S.
  • 7 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
  • 8 Ageno W, Agnelli G, Imberti D. et al. Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the MASTER registry. Intern Emerg Med. 2011 epub ahead of print.
  • 9 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2012; 363: 2499-2510.
  • 10 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica 2007; 92: 199-205.
  • 11 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
  • 12 Hansson PO, Welin L, Tibblin G. et al. Deep vein thrombosis and pulmonary embolism in the general population. The Study of Men Born in 1913. Arch Intern Med 1997; 157: 1665-1670.
  • 13 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
  • 14 Ageno W, Prandoni P, Romualdi E. et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 04: 1914-1918.
  • 15 Severinsen MT, Kristensen SR, Johnsen SP. et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 07: 1297-1303.
  • 16 Squizzato A, Romualdi E, Büller HR. et al. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
  • 17 Squizzato A, Romualdi E, Piantanida E. et al. Sub-clinical hypothyroidism and deep venous thrombosis. A pilot, cross-sectional study. Thromb Haemost 2007; 97: 803-806.
  • 18 Segal JB, Brotman DJ, Necochea AJ. et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. J Am Med Assoc 2009; 301: 2472-2485.
  • 19 Tichelaar YIGV, Kluin-Nelemans JC, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis, a systematic review. Thromb Haemost 2012; 107: 827-837.
  • 20 Dentali F, Nicolini E, Ageno W. Venous and arterial thrombosis associated with HIV infection. Semin Thromb Hemost. 2012 epub ahead of print.
  • 21 Squizzato A, Gerdes VE, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93: 403-410.
  • 22 Eichinger S, Hron G, Bialonczyk C. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
  • 23 Novacek G, Weltermann A, Sobala A. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787.